



Figure 1: Portrait of Konrad Stawiski

Konrad Stawiski

Radiation oncologist and clinical-translational researcher

I'm a **radiation oncologist** and **researcher** focused on clinical radiotherapy, oncology data science, molecular biomarkers, radiomics, and practical medical AI. My clinical work covers radiotherapy broadly, with a special focus on genitourinary and gastrointestinal cancers.

- Full name: **Konrad Grzegorz Stawiski**
- Nationality: Polish
- E-mails: konrad@konsta.com.pl, konrad.stawiski@umed.lodz.pl, konradg_stawiski@dfci.harvard.edu, kstawisk@broadinstitute.org
- Selected links: [Harvard Catalyst](#), [Radioonkolog.pl](#), [ORCID](#), [PubMed](#), [OpenAlex](#), [Google Scholar](#), [GitHub](#)

Summary

Konrad G. Stawiski is a board-certified radiation oncologist and clinical-translational researcher focused on GU/GI radiotherapy, bladder, prostate and rectal cancer care, radiomics, omics biomarkers, radiation-toxicity modeling, and practical medical AI.

He is a Visiting Assistant Professor of Radiation Oncology at Dana-Farber Cancer Institute, an Assistant Professor at the Medical University of Lodz, and Deputy Head of a 34-bed Brachytherapy and General Oncology Department at Copernicus Memorial Hospital in Lodz.

The curated Google Scholar publication list contains 93 records; the profile reports an h-index of 19 and 1,095 citations. He is Partner PI and Polish group lead in the ERA PerMed miRPOC consortium, PI of the NCN PRELUDIUM and Radonek-AI projects, co-inventor on circulating microRNA patent families, and a clinical-trial subinvestigator in phase I/II-III oncology studies.

His research outputs include selected open research software and digital-health tools, translational biomarker studies, radiotherapy-data pipelines, clinical AI work, and editorial service as an Editorial Board Member of BMC Cancer.

Employment history

- 2026 - present: **Visiting Assistant Professor of Radiation Oncology**, Department of Radiation Oncology, [Dana-Farber Cancer Institute](#), Boston, MA, USA.
- 2024 - present: **Assistant Professor**, [Department of Biostatistics and Translational Medicine](#), Medical University of Lodz, Poland
 - Supervisor of the "Artificial Intelligence in Oncology" Students' Scientific Group.
 - Lecturer in Biostatistics, Translational Medicine, Research Methodology, and AI, including data mining and deep learning.
 - Engaged in cancer research, focusing on bioinformatics and omic data analysis (radiomics, NGS sequencing - miRNA-seq, bulk/sc RNA-seq, WXS).
 - Polish group lead in the ERA PerMed miRPOC international consortium.
- 2023 - present: **Radiation Oncologist**, **Deputy Head of Department of Brachytherapy and General Oncology**, [Regional Oncology Centre, Copernicus Memorial Hospital](#), Lodz, Poland
 - Deputy clinical lead for a 34-bed ward, coordinating external-beam radiotherapy, brachytherapy, concurrent chemoradiotherapy, and general oncology inpatient care.
 - Radiation oncologist with a broad radiotherapy practice and special focus on genitourinary and gastrointestinal cancers, especially prostate, bladder, and rectal cancer, including prostate radiotherapy, bladder-preserving trimodality treatment/radio-chemotherapy, rectal cancer chemoradiotherapy, and multidisciplinary uro-oncology (see <https://radioonkolog.pl> for clinical activities). Serving as subinvestigator in commercial and non-commercial clinical trials.
 - Performing stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), radiochemotherapy, and radioimmunotherapy.
- 2022 - 2023: **Research Fellow** in Radiation Oncology ([Mouw Lab](#) and [Carvalho Lab](#)), Dana-Farber Cancer Institute/Harvard Medical School/Broad Institute of MIT and Harvard, Boston, MA, USA
- 2021 - 2023: **Research and Teaching Assistant**, [Department of Biostatistics and Translational Medicine](#), Medical University of Lodz, Poland

- 2018 - 2023: **Radiation Oncology Resident Physician**, [Regional Oncology Centre, Copernicus Memorial Hospital](#), Lodz, Poland
 - Physician in Department of Radiotherapy and on-call physician in Radiotherapy and Oncology Ward (reference: Prof. Jacek Fijuth, M.D., Ph.D.),
 - Additional experience as on-call physician in Hematooncology Ward (reference: Prof. Piotr Smolewski, M.D., Ph.D.).
- 2017 - 2018: **Bioinformatics and Medical Informatics Specialist**, [Department of Biostatistics and Translational Medicine](#), Medical University of Lodz, Poland
- 2016 - 2017: **Medical Post-graduate Internship**, [Clinical Hospital of the Ministry of the Interior and Administration in Lodz](#), Lodz, Poland

Clinical, research and software profile

Broad radiotherapy practice with a genitourinary and gastrointestinal focus; radiomics and radiotherapy-data pipelines; translational biomarkers; reproducible oncology analyses; and selected research-software and digital-health projects.

Education

- 2023: **Board Certification in Radiation Oncology**, Medical Examinations Center (CEM) in Poland.
- 2016 - 2021: **Doctor of Philosophy (PhD)** (doctorate), Department of Biostatistics and Translational Medicine (reference: Wojciech Fendler, M.D., Ph.D.; <https://biostat.umed.pl>):
 - Dissertation: **Głębokie sztuczne sieci neuronowe w integracji profilu ekspresji krążących i wewnątrzkomórkowych cząsteczek miRNA pacjentów z rakiem trzustki.** (Deep learning-based integration of circulating and cellular miRNA expression of pancreatic cancer.)
- 2017: Full medical license in Poland (PWZ: 3347648)
- 2010 - 2016: **Doctor of Medicine (MD)** (6-year M.D. Program; grade: very good), [Faculty of Medicine, Medical University of Lodz \(Poland\)](#)

Internships

- 2026: [Prof. Franciszek Walczak NAWA scholarship](#) for a 6-month research stay at Dana-Farber Cancer Institute/Harvard Medical School focused on radiotherapy research in bladder cancer, including bladder-sparing strategies.
- 2022-2023: Bekker NAWA (6 months) research fellowship in Dana-Farber Cancer Institute/Harvard Medical School/Broad Institute of MIT and Harvard, Boston, MA, USA (reference: Kent Mouw, M.D., Ph.D.)
- 2016: [ERASMUS+ research internship](#) at the EPSRC Centre for Mathematical and Statistical Analysis of Multimodal Clinical Imaging, University of Cambridge, Cambridge, UK, focused on real-time TRUS-MRI fusion software for prostate cancer biopsy (reference: Prof. John Aston, Ph.D.)
- 2015: IFMSA research exchange (6 weeks), Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Upstate Medical University, Syracuse, NY, USA (reference: Stephen J. Glatt, Ph.D.)
- 2014: neurosurgical clinical clerkship (3 weeks), University Hospital Southampton NHS Trust, Southampton, UK (reference: Paul Grundy, M.D.)
- 2013: medical clinical clerkship (4 weeks), Mubarak Al Kabeer Hospital, Kuwait City, Kuwait (reference: Ibrahim T. Lasheen, M.D.)

Research grants, funded projects and innovation work

- 2023 - present: [ERA PerMed Consortium \(Joint Transnational Call 2022\)](#), miRPOC - miRNA as biomarkers in early detection and personalised treatment in ovarian cancer; total consortium budget approximately EUR 1,000,000; **Partner PI / Polish group lead** at Medical University of Lodz; consortium with Cancer Registry of Norway/Oslo University Hospital, German Cancer Research Center and Brigham and Women's Hospital/Harvard Medical School.
- 2023 - 2024: [Radonek-AI - virtual oncology patient assistant](#), PLN 70,000, Student Scientific Circles Create Innovations programme, Polish Ministry of Education **[PI]**
- 2019 - 2022: NCN PRELUDIUM [ID: UM0-2018/29/N/NZ5/02422], Deep artificial neural networks in the integration of the expression profile of circulating and intracellular miRNA molecules in pancreatic cancer patients. 209 860 PLN **[PI]**
- 2014 - 2015: Ministry of Science and Higher Education Generation of the Future [ID: MNiSzw/2014/DIR/379/GPII], PancreApp: application of the eight-dimensional Shepard approximation in the individualization of nutritional recommendations, with particular emphasis on chronic pancreatitis, PLN 37,800 **[PI]**
- 2017 - 2018: Specialist in bioinformatics and medical informatics (building an internet platform to collect data for the research purposes of the project) in the project "Lodz Program for HNSCC Prevention" [ID: POWR.05.01.00-00-0011/16] co-financed by the European Union as part of the European Social Fund (European Social Fund, 1 792 260 PLN)
- 2019-2021: Researcher in the study "Predictive Biomarkers of Radiation Toxicity (PBRTox)" [ID: P0IR.04.04.00-00-2280/16] under the supervision of prof. Wojciech Fendler (Foundation for Polish Science; 1 999 651 PLN)
- 2014-2016: Researcher in the study "Profile of circulating microRNAs in the diagnosis of rare forms of diabetes" [ID: 2012/05/E/NZ5/02130] under the supervision of prof. Wojciech Fendler (NCN SONATA BIS; 1 489 800 PLN)

Awards, honours and scholarships

- 2025: [Prof. Franciszek Walczak NAWA Programme Scholarship](#), Polish National Agency for Academic Exchange; one of 31 awardees selected from 125 applications in the 2025 call (25% success rate; funding up to PLN 29,500/month), for a 6-month Dana-Farber / Harvard Medical School fellowship on bladder-preserving treatment strategies in muscle-invasive bladder cancer; institutional report: application score 94/100.
- 2025: [First place for final research project](#) in the Harvard Medical School / Polish Medical Research Agency Clinical Scholars Research Training programme, for a project on rectal cancer radiochemotherapy.
- 2022: [Rector's Award for Research Achievements in 2021](#), Medical University of Lodz, team award for publication series on urologic cancer (12.919 IF).
- 2022: Best biostatistics Ph.D. thesis in 2021 (Awarded by StatSoft Polska).
- 2022: Implementation Activity Award of Polish Ministry of Science, for work involving the implementation of diagnostic tests based on free-circulating microRNAs into clinical practice.
- 2021: [Scholarship of Polpharma Scientific Foundation](#) for best Ph.D. students, awarded for the dissertation on deep artificial neural networks integrating circulating and intracellular miRNA profiles in pancreatic cancer.
- 2020: Scholarship for the best Ph.D. students at the Medical University of Lodz.
- 2019: Scholarship for the best Ph.D. students at the Medical University of Lodz.
- 2018: Scholarship for the best Ph.D. students at the Medical University of Lodz.
- 2017: Scholarship for the best Ph.D. students at the Medical University of Lodz.
- 2016: Scholarship for the best Ph.D. students at the Medical University of Lodz.
- 2016: Scholarship of the City of Lodz for the best Ph.D. students.
- 2016: Winner of Adzuna's Polish "Graduate of the Year" contest.
- 2015: Scholarship of Minister of Science and Higher Education & Minister of Health of Republic of Poland for outstanding achievements for students in the academic year 2015/2016.
- 2015: Scholarship of Marshal of the Lodzkie Region (highest degree)
- 2014: Distinction in a nationwide competition "Studencki Nobel" (Eng. "Student's Nobel Prize").
- 2014: Special Award for the Youngest Winner of the Session at the conference 10. International & 52. Polish Training & Scientific Medical Congress of Students' Scientific Societies and Junior Doctors "Juvenes Pro Medicina" 2014 in Łódź (founder: Aldona Ochęcka-Szymańska M.D., Ph.D.)
- 2013: Scholarship of Minister of Science and Higher Education of Republic of Poland for outstanding achievements for students in the academic year 2013/2014;

Patents and commercializations

- [WO2023283476A2](#), [CA3223723A1](#), and [AU2022306397A1](#), entitled "Circulating microRNA signatures for pancreatic cancer"; assignees include Medical University of Lodz and Dana-Farber Cancer Institute Inc.
- [EP3565903](#), [US20200123614A1](#), [US11214839B2](#), and [US12385099](#), entitled "Circulating microRNA signatures for ovarian cancer"; assignees include Medical University of Lodz, Brigham and Women's Hospital Inc., and Dana-Farber Cancer Institute Inc.; patent record indexed by [PublicUM](#); publicly described as under commercialization/licensing efforts with Aspira Women's Health (A15876-ELA-ASPIRA).

Research

Bibliometrics

Google Scholar: h-index = 19; citations = 1,095; publication records = 95.

For formal publication review, use PubMed, ORCID, and OpenAlex as authoritative records.

International collaboration network

OpenAlex currently identifies publication coauthors affiliated with 16 countries outside Poland. Most frequently represented: United States (44), United Kingdom (7), Greece (5), Hungary (5).





Figure 2: Citations by year and publication records by year from the curated Google Scholar data.

Publication collaboration footprint

Coauthor–affiliation countries recorded for OpenAlex works



Poland is outlined as the home base. Source: OpenAlex; each work is counted once per country.

The map is generated in R from cached OpenAlex Works metadata and refreshed through the publication-data workflow.

Selected publications and contributions

- **First author / GU translational oncology:** Stawiski K, Perera-Bel J, Rodriguez-Vida A, Juanpere N, Lee J, Michaud DE, Guerriero JL, Mouw KW, Bamias A, Carvalho FLF, Bellmunt J. **Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma.** *Molecular Oncology*. 2026 Jun 1. doi: [10.1002/1878-0261.70276](https://doi.org/10.1002/1878-0261.70276). Role: first author; tumor immune microenvironment and platinum-treated urothelial carcinoma.
- **Bladder cancer / DFCI-Broad collaboration:** Zhou Y, Borcsok J, Adib E, Kamran SC, Neil AJ, Stawiski K, et al. **ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.** *Science Advances*. 2023;9:eadg2263. doi: [10.1126/sciadv.adg2263](https://doi.org/10.1126/sciadv.adg2263). Role: co-author in translational bladder cancer work aligned with bladder-preserving research.
- **Clinical AI / urologic oncology:** Jobczyk M, Stawiski K, Kaszkowiak M, Rajwa P, Rozanski W, Soria F, et al. **Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer.** *European Urology Oncology*. 2022;5:109-112. Role: clinical-AI and prediction-modeling collaborator.
- **Research software / omics modeling:** Stawiski K, Kaszkowiak M, Mikulski D, Hogendorf P, Durczynski A, et al. **OmicSelector: automatic feature selection and deep learning modeling for omic experiments.** *bioRxiv*. 2022. doi: [10.1101/2022.06.01.494299](https://doi.org/10.1101/2022.06.01.494299). Role: first author and software lead.
- **miRNA biomarker validation:** Stawiski K, Fortner RT, Pestarino L, Umu SU, Kaaks R, Rounge TB, et al. **Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches.** *Frontiers in Oncology*. 2024;14:1389066. Role: first author; machine-learning validation of circulating miRNA biomarkers.

- **Patent-linked translational diagnostics:** Elias KM, Fendler W, Stawiski K, Fiascone SJ, Vitonis AF, Berkowitz RS, et al. **Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer.** *eLife*. 2017;6:e28932. Role: computational biomarker collaborator in patent-linked translational work.
- **Radiation biomarker work:** Nowicka Z, Tomasik B, Kozono D, Stawiski K, Johnson T, Haas-Kogan D, et al. **Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study.** *Radiotherapy and Oncology*. 2023;185:109731. Role: biomarker and radiation-response collaborator.
- **Radiation toxicity / dose-volume analytics:** Nowicka Z, Kuna K, Laszczyc M, Lazar-Poniatowska M, Sobocki BK, Stawiski K, et al. **Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques.** *Physics and Imaging in Radiation Oncology*. 2024;30:100593. Role: radiotherapy data and prediction-modeling collaborator.

Authoritative full records: [PubMed](#), [ORCID](#), [OpenAlex](#), and [Google Scholar](#).

Google Scholar publication records

- B Tomasik, M Jąkowski, M Bieńkowski, J Teodorczyk, BK Sobocki, ... **Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomics** *Journal of Translational Medicine* 2026: 24 (1), 587 [citations: 1]
- JW Webber, L Wollborn, S Mishra, S Alimena, B Testino, K Stawiski, ... **A lasso-based model combining miRNA and clinical variables predicts future risk of breast and ovarian cancer** *Scientific Reports* 2026 [citations: 0]
- K Kuna, J Burzyński, D Mikulski, B Sobocki, A Papis-Ubych, K Stawiski, ... **Serum citrulline as a prognostic marker in patients with oropharyngeal carcinoma treated with chemoradiotherapy** *Contemporary Oncology/Współczesna Onkologia* 2026: 29 (1) [citations: 0]
- K Stawiski, J Perera-Bel, A Rodriguez-Vida, N Juanpere, J Lee, ... **Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma** *Molecular Oncology* 2026: doi: 10.1002/1878-0261.70276 [citations: 0]
- M Golinska, A Rycerz, M Sobczak, J Chrzanowski, K Stawiski, W Fendler **Complement and coagulation cascade cross-talk in endometriosis and the potential of Janus Kinase inhibitors-a network meta-analysis** *Frontiers in Immunology* 2025: 16, 1619434 [citations: 12]
- M Pajdziński, J Burzyński, A Zięba, N Jędrzejczak, J Fijuth, K Stawiski **4474 Risk of Neutropenia With or Without Daratumumab in Bortezomib-Based First-Line Chemotherapy and Radiotherapy for Multiple Myeloma: A Pilot Study** *Radiotherapy and Oncology* 2025: 206, S919-S920 [citations: 0]
- K Stawiski, A der Rycerz, J Burzyński, K Kasper, W Fendler **4567 Radonek-Fine-Tuned GPT-4o for Radiation Oncology Patient Support: Preliminary Evaluation and Protocol for Prospective Validation** *Radiotherapy and Oncology* 2025: 206, S2417-S2418 [citations: 0]
- MM Pietrzak, W Pietruszewska, M Barańska, A Rycerz, K Stawiski, ... **Assessment of the Interdependencies Between High-Speed Videoendoscopy and Simultaneously Recorded Audio Data in Various Glottal Pathologies** *Biomedicines* 2025: 13 (2), 511 [citations: 0]
- D Chowdhury, KM Elias, W Fendler, K Stawiski **Circulating microrna signatures for ovarian cancer** *US Patent* 2025: 12,385,099 [citations: 0]
- D Chowdhury, W Fendler, K Stawiski **Circulating microrna signatures for pancreatic cancer** *US Patent App.* 2025: 18/577,387 [citations: 0]
- S Kołowacik, BJ Bińkowski, K Stawiski, J Drożdż **Time efficiency and safety of antazoline in the rapid cardioversion of recent onset atrial fibrillation during supraventricular arrhythmias ablation** *Polish Heart Journal (Kardiologia Polska)* 2025: 83 (2), 203-206 [citations: 0]
- K Stawiski, J Perera-Bel, A Rodriguez-Vida, N Juanpere Rodero, J Lee, ... **Tumor B cell infiltration in platinum-treated advanced urothelial carcinoma** *bioRxiv* 2025: 2025.02. 27.640395 [citations: 0]
- FLF Carvalho, J Lee, N Kalavros, Y Zhou, D Michaud, I Stelter, H Siddiqui, ... **Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer** *bioRxiv* 2025: 2025.09. 08.674862 [citations: 0]
- Z Nowicka, K Kuna, M Łaszczyk, M Łazar-Poniatowska, BK Sobocki, ... **Dose-volume metric-based prediction of radiotherapy-induced lymphocyte loss in patients with non-small-cell lung cancer treated with modern radiotherapy techniques** *Physics and Imaging in Radiation Oncology* 2024: 30, 100593 [citations: 12]
- P Brady, A Yousif, N Sasamoto, AF Vitonis, W Fendler, K Stawiski, ... **Plasma microRNA expression in adolescents and young adults with endometriosis: the importance of hormone use** *Frontiers in Reproductive Health* 2024: 6, 1360417 [citations: 8]
- A Puła, T Robak, I Dróżdż, K Stawiski, A Rycerz, M Misiewicz, P Robak **Circulating serum microRNAs as biomarkers of drug resistance in multiple myeloma patients treated with bortezomib-based regimens-pilot study** *Leukemia & Lymphoma* 2024: 65 (2), 257-264 [citations: 4]
- Z Nowicka, K Kuna, M Łaszczyk, K Stawiski, B Tomasik, W Fendler **Effect of the time-of-day of radiotherapy administration on radiation-induced lymphocyte depletion in lung cancer** *International Journal of Radiation Oncology, Biology, Physics* 2024: 120 (2), e52 [citations: 3]
- K Stawiski, RT Fortner, L Pestarino, SU Umu, R Kaaks, TB Rounge, ... **Validation of miRNA signatures for ovarian cancer earlier detection in the pre-diagnosis setting using machine learning approaches** *Frontiers in oncology* 2024: 14, 1389066 [citations: 3]
- Z Nowicka, K Kuna, K Stawiski, J Sołek, M Świderek, A Papis-Ubych, ... **Extreme acute radiation-induced toxicity in a patient with polymorphous low-grade adenocarcinoma of the nasopharynx and rare variants in DNA repair genes** *Head & Neck* 2024: 46 (2), E10-E17 [citations: 1]
- D Mikulski, M Nowicki, I Dróżdż, E Perdas, P Strzałka, K Kościelny, ... **MicroRNAs predict early complications of autologous**

- hematopoietic stem cell transplantation** *Biomarker Research* 2024: 12 (1), 42 [citations: 1]
- K Stawiski, M Bilski, J Nowak-Potemska, M Bilewicz, J Fijuth **Radiation induced lymphopenia depends on lymph node irradiation in prostate cancer radiotherapy** *International Journal of Radiation Oncology, Biology, Physics* 2024: 120 (2), e549-e550 [citations: 1]
 - JW Webber, L Wollborn, S Mishra, AF Vitonis, DW Cramer, RT Phan, ... **Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass** *Gynecologic Oncology* 2024: 190, 124-130 [citations: 1]
 - M Masłowski, K Stawiski, A Zięba, D Mikulski, J Bednarek, J Fijuth **1994: Predicting neutropenia dynamics after RT in first-line Bortezomib-based chemo for MM-a pilot study** *Radiotherapy and Oncology* 2024: 194, S1165-S1168 [citations: 0]
 - K Stawiski, M Pajdziński, A Zięba, M Masłowski, J Fijuth **3178: Development of a CT-only autosegmentation model for hippocampal delineation in radiation therapy.** *Radiotherapy and Oncology* 2024: 194, S3165-S3166 [citations: 0]
 - CJ Magnani, VD DAndrea, K Stawiski, I Stelter, T Hanlon, L Jia, AS Kibel, ... **AIRD1A knockouts in bladder cancer cell lines leads to MYC and E2F activation implicated in more aggressive tumor behavior** *European Urology* 2024: 85, S219-S220 [citations: 0]
 - F Mohammed, K Stawiski, HS Musa, SK Owolabi, S Abubakar, SO Rotimi, ... **Co-expression of HERV-R, CCND1, BRAF, FOXA1, TMPRSS2, ATF4 and low expression of BAZ1B and KMT2D is associated with early detection and poor prognosis of prostate cancer in ...** *Cancer Research* 2024: 84 (6_Supplement), 6432-6432 [citations: 0]
 - Z Nowicka, K Kuna, M Łaszczych, M Łazar-Poniatowska, BK Sobocki, ... **Physics and Imaging in Radiation Oncology** *Oncology* 2024: 30 [citations: 0]
 - BA Łochowska, K Stawiski, K Kuna, Z Nowicka, M Łochowski, J Fijuth **Predicting overall survival in non-small cell lung cancer patients receiving concurrent radiochemotherapy and adjuvant durvalumab-a Polish real-world single-center experience** *Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory* 2024: 9 (3), 190-196 [citations: 0]
 - A Suleja, M Bliski, E Laukhtina, P Rajwa, K Stawiski, M Miszczyk **Radioterapia stereotaktyczna (SBRT) w leczeniu pierwotnie zlokalizowanego raka nerkowokomórkowego (RCC)-przegląd systematyczny i metaanaliza** *Biuletyn Polskiego Towarzystwa Onkologicznego NOWOTWORY* 2024: 9 (Suppl. 1) [citations: 0]
 - FLF De Carvalho, J Lee, K Bi, B Titchen, K Stawiski, J Park, A Garza, ... **Tumor-immune interactions and cisplatin resistance in localized muscle-invasive bladder cancer** *Cancer Research* 2024: 84 (6_Supplement), 7041-7041 [citations: 0]
 - M Miszczyk, Ł Magrowski, T Krzysztofiak, R Stando, W Majewski, ... **Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group ...** *Radiotherapy and Oncology* 2023: 183, 109632 [citations: 29]
 - Y Zhou, J Börcsök, E Adib, SC Kamran, AJ Neil, K Stawiski, D Freeman, ... **ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer** *Science advances* 2023: 9 (47), eadg2263 [citations: 25]
 - K Elias, U Smyczynska, K Stawiski, Z Nowicka, J Webber, J Kaplan, ... **Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles** *Nature communications* 2023: 14 (1), 3350 [citations: 20]
 - Z Nowicka, B Tomasik, D Kozono, K Stawiski, T Johnson, D Haas-Kogan, ... **Serum miRNA-based signature indicates radiation exposure and dose in humans: a multicenter diagnostic biomarker study** *Radiotherapy and Oncology* 2023: 185, 109731 [citations: 12]
 - J Malinowski, W Pietruszewska, K Stawiski, MM Pietrzak, M Barańska, ... **High-speed videoendoscopy enhances the objective assessment of glottic organic lesions: a case-control study with multivariable data-mining model development** *Cancers* 2023: 15 (14), 3716 [citations: 5]
 - M Masłowski, K Stawiski, A Zięba, D Mikulski, J Bednarek, J Fijuth **Predicting neutropenia dynamics after radiation therapy in multiple myeloma patients receiving first-line bortezomib-based chemotherapy-a pilot study** *Biuletyn Polskiego Towarzystwa Onkologicznego Nowotwory* 2023: 8 (4), 274-283 [citations: 1]
 - K Stawiski, J Perera-Bel, A Rodriguez-Vida, NJ Rodero, KW Mouw, ... **Assessing tumor-infiltrating immune cells and outcomes with cisplatin-versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum ...** *Journal of Clinical Oncology* 2023: 41 (16_suppl), 4583-4583 [citations: 0]
 - M Jobczyk, K Stawiski, M Kaszkowiak, P Rajwa, W Różański, F Soria, ... **Deep learning-based recalibration of the CUETO and EORTC prediction tools for recurrence and progression of non-muscle-invasive bladder cancer** *European urology oncology* 2022: 5 (1), 109-112 [citations: 37]
 - K Mieczkowski, K Kitowska, M Braun, B Galikowska-Bogut, ... **FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer** *Molecular Oncology* 2022: 16 (15), 2823-2842 [citations: 22]
 - Ł Kuncman, M Orzechowska, K Stawiski, M Masłowski, M Ciężyńska, ... **The kinetics of FMS-related tyrosine kinase 3 ligand (Flt-3L) during chemoradiotherapy suggests a potential gain from the earlier initiation of immunotherapy** *Cancers* 2022: 14 (16), 3844 [citations: 17]
 - M Panek, K Stawiski, M Kaszkowiak, P Kuna **Cytokine TGFbeta gene polymorphism in asthma: TGF-related SNP analysis enhances the prediction of disease diagnosis (a case-control study with multivariable data-mining model ...** *Frontiers in immunology* 2022: 13, 746360 [citations: 14]
 - K Stawiski, M Kaszkowiak, D Mikulski, P Hogendorf, A Durczyński, ... **OmicSelector: automatic feature selection and deep learning modeling for omic experiments** *BioRxiv* 2022: 2022.06. 01.494299 [citations: 12]
 - W Fendler, B Tomasik, K Atkins, K Stawiski, J Chałubińska-Fendler, ... **The clinician's guide to radiotherapy complications** *Polskie Archiwum Medycyny Wewnętrznej* 2022: 132 (1) [citations: 10]
 - A Gockley, K Pagacz, S Fiascone, K Stawiski, N Holub, K Hasselblatt, ... **A translational model to improve early detection of epithelial ovarian cancers** *Frontiers in Oncology* 2022: 12, 786154 [citations: 8]
 - M Miszczyk, J Rembak-Szynkiewicz, Ł Magrowski, K Stawiski, ... **The prognostic value of PI-RADS score in CyberKnife ultra-hypofractionated**

- radiotherapy for localized prostate cancer** *Cancers* 2022: 14 (7), 1613 [citations: 8]
- E J Bobeff, M Bukowiecka-Matusiak, K Stawiski, K Wiśniewski, ... **Plasma amino acids may improve prediction accuracy of cerebral vasospasm after aneurysmal subarachnoid haemorrhage** *Journal of Clinical Medicine* 2022: 11 (2), 380 [citations: 6]
 - S Kubik, D Jesioneck-Kupnicka, K Stawiski, J Fijuth, ... **Clinical significance of CD34, podoplanin and Ki-67 expression in patients with locally advanced squamous cell cervical carcinoma** *Journal of Obstetrics and Gynaecology* 2022: 42 (6), 2248-2254 [citations: 5]
 - E J Bobeff, K Stawiski, PA Stanisławska, BJ Posmyk, K Wiśniewski, M Bryl, ... **Validation of the elderly traumatic brain injury score: observational case control study** *World neurosurgery* 2022: 161, e464-e472 [citations: 5]
 - D Chowdhury, KM Elias, W Fendler, K Stawiski **Circulating microRNA signatures for ovarian cancer** *US Patent* 2022: 11,214,839 [citations: 3]
 - K Stawiski, M Masłowski, W Masłowska, M Kordzińska, B Lochowska, ... **Clinical and Radiomics-Based Deep Learning Predictive Model for Early Treatment Failure after Neoadjuvant Radiochemotherapy for Rectal Cancer** *International Journal of Radiation Oncology, Biology, Physics* 2022: 114 (3), e150 [citations: 0]
 - M Panek, K Stawiski, M Kaszkowiak, P Kuna **Cytokine TGFbeta gene polymorphisms in asthma** *Frontiers in Immunology* 2022: 13 [citations: 0]
 - A Napieralska, J Bochenek-Cibor, A Chyrek, M Konkol, E Pawłowska, ... **Improving Education in Radiation Oncology in Poland** *International Journal of Radiation Oncology, Biology, Physics* 2022: 114 (1), e4-e5 [citations: 0]
 - D Mikulski, M Nowicki, I Drózdź, E Perdas, P Strzałka, K Kościelny, ... **Serum miRNA-based neural network models for predicting complications in patients receiving high-dose melphalan or BeEAM conditioning chemotherapy.** *Acta Haematologica Polonica* 2022: 53 [citations: 0]
 - M Miszczyk, J Ciepał, R Stando, O Masri, I Jabłońska, K Stawiski, ... **The Association between Dose Escalation and Risk of Developing Metastases in Intermediate and High-Risk Prostate Cancer Patients Treated with Radiotherapy** *International Journal of Radiation Oncology, Biology, Physics* 2022: 114 (3), e231 [citations: 0]
 - M Miszczyk, E Staniewska, I Jabłońska, A Lipka-Rajwa, K Stawiski, ... **Volumetric staging in radiotherapy for oropharyngeal cancers** *Tumori Journal* 2022: 108 (6), 586-591 [citations: 0]
 - P Robak, D Jarych, D Mikulski, I Drózdź, E Węglowska, A Kotkowska, ... **The prognostic value of whole-blood PSMB5, CXCR4, POMP, and RPL5 mRNA expression in patients with multiple myeloma treated with bortezomib** *Cancers* 2021: 13 (5), 951 [citations: 23]
 - B Tomasik, A Papis-Ubych, K Stawiski, J Fijuth, P Kędzierawski, ... **Serum microRNAs as xerostomia biomarkers in patients with oropharyngeal cancer undergoing radiation therapy** *International Journal of Radiation Oncology Biology* Physics* 2021: 111 (5), 1237-1249* [citations: 18]
 - P Michał, S Konrad, K Piotr **TGF-beta gene polymorphisms as risk factors for asthma control among clinic patients** *Journal of Inflammation* 2021: 18 (1), 28 [citations: 13]
 - L Lee, B Howitt, T Cheng, M King, K Stawiski, W Fendler, D Chowdhury, ... **MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma** *Gynecologic oncology* 2021: 163 (3), 453-458 [citations: 9]
 - D Mikulski, I Drózdź, E Perdas, K Stawiski, M Nowicki, M Misiewicz, ... **Changes in the microRNA expression profile in patients undergoing autologous stem cell transplantation** *Blood* 2021: 138, 4789 [citations: 5]
 - M Miszczyk, W Majewski, K Stawiski, K Rasławski, P Rajwa, I Jabłońska, ... **Prognostic factors in postoperative radiotherapy for prostate cancer-tertiary center experience** *Radiology and Oncology* 2021: 55 (2), 203 [citations: 4]
 - Z Nowicka, R Bibik, R Stando, W Fendler, K Stawiski, B Tomasik **A link between seasonality and radiation-related toxicity: The big time or time will tell?** *Radiotherapy and Oncology* 2021: 161, 257-258 [citations: 2]
 - ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, ... **Correction to: A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence** *BMC genomics* 2021: 22 (1), 327-327 [citations: 1]
 - ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, ... **A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced senescence (vol 19, 37 ...** *BMC GENOMICS* 2021: 22 (1) [citations: 0]
 - B Małachowska, B Tomasik, K Stawiski, S Kulkarni, C Guha, ... **Circulating microRNAs as biomarkers of radiation exposure: a systematic review and meta-analysis** *International Journal of Radiation Oncology Biology* Physics* 2020: 106 (2), 390-402* [citations: 64]
 - M Jobczyk, K Stawiski, W Fendler, W Różański **Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC ...** *Cancer Medicine* 2020: 9 (11), 4014-4025 [citations: 59]
 - P Robak, I Drózdź, D Jarych, D Mikulski, E Węglowska, M Siemieniuk-Ryś, ... **The value of serum microRNA expression signature in predicting refractoriness to bortezomib-based therapy in multiple myeloma patients** *Cancers* 2020: 12 (9), 2569 [citations: 28]
 - Ł Kuncman, K Stawiski, M Masłowski, J Kucharz, J Fijuth **Dose-volume parameters of MRI-based active bone marrow predict hematologic toxicity of chemoradiotherapy for rectal cancer** *Strahlentherapie und Onkologie* 2020: 196 (11), 998-1005 [citations: 27]
 - M Braun, D Piasecka, B Tomasik, K Mieczkowski, K Stawiski, A Zielinska, ... **Hormonal receptor status determines prognostic significance of FGFR2 in invasive breast carcinoma** *Cancers* 2020: 12 (9), 2713 [citations: 17]
 - Z Nowicka, B Tomasik, DE Kozono, K Stawiski, TJ Johnson, ... **Serum Circulating MicroRNAs as Functional Biodosimeters in Patients Undergoing Total Body Irradiation** *International Journal of Radiation Oncology, Biology, Physics* 2020: 108 (3), e536 [citations: 0]
 - Z Nowicka, K Stawiski, B Tomasik, W Fendler **Extracellular miRNAs as biomarkers of head and neck cancer progression and**

- metastasis** *International journal of molecular sciences* 2019: 20 (19), 4799 [citations: 45]
- A Zmysłowska, A Waszczykowska, D Baranska, K Stawiski, M Borowiec, ... **Optical coherence tomography and magnetic resonance imaging visual pathway evaluation in Wolfram syndrome** *Developmental Medicine & Child Neurology* 2019: 61 (3), 359-365 [citations: 27]
 - EJ Bobeff, J Fortuniak, B Bryszewski, K Wiśniewski, M Bryl, K Kwiecień, ... **Mortality after traumatic brain injury in elderly patients: a new scoring system** *World neurosurgery* 2019: 128, e129-e147 [citations: 26]
 - M Kotlicka-Antczak, MS Karbownik, K Stawiski, A Pawełczyk, N Żurner, ... **Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state** *European Psychiatry* 2019: 58, 72-79 [citations: 26]
 - M Zakrzewska, R Gruszka, K Stawiski, W Fendler, J Kordacka, ... **Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glia tumors** *BMC cancer* 2019: 19 (1), 544 [citations: 17]
 - EJ Bobeff, BJ Posmyk, K Bobeff, J Fortuniak, K Wiśniewski, K Stawiski, ... **Predicting outcome and conservative treatment failure in patients with skull fracture after traumatic brain injury: a retrospective cohort study** *Journal of Neurological Surgery Part A: Central European Neurosurgery* 2019: 80 (06 ... [citations: 5]
 - L Kuncman, K Stawiski, M Masłowski, J Wilczyńska, J Bury, J Fijuth **FT3-L Dynamics in Blood Could be Predictive of Time of Occurrence Lymphocyte Nadir in Patients Undergoing Preoperative Chemoradiotherapy for Rectal Cancer.** *International Journal of Radiation Oncology, Biology, Physics* 2019: 105 (1), E167-E168 [citations: 0]
 - ES Komseli, IS Pateras, T Krejsgaard, K Stawiski, SV Rizou, A Polyzos, ... **A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-RNAs and proteins in situ during oncogene-induced ...** *BMC genomics* 2018: 19 (1), 37 [citations: 61]
 - K Pagacz, K Stawiski, A Szadkowska, W Młynarski, W Fendler **GlyCulator2: an update on a web application for calculation of glycemic variability indices** *Acta diabetologica* 2018: 55 (8), 877-880 [citations: 37]
 - A Puła, K Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak **Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized ...** *Leukemia & Lymphoma* 2018: 59 (5), 1084-1094 [citations: 24]
 - K Stawiski, I Pietrzak, W Młynarski, W Fendler, A Szadkowska **NIRCa: An artificial neural network-based insulin resistance calculator** *Pediatric Diabetes* 2018: 19 (2), 231-235 [citations: 15]
 - KM Elias, W Fendler, K Stawiski, SJ Fiascone, AF Vitonis, RS Berkowitz, ... **Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer** *elife* 2017: 6, e28932 [citations: 174]
 - J Trelinska, I Dachowska, D Baranska, K Stawiski, K Kotulska, W Fendler, ... **Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study)** *Pediatric blood & cancer* 2017: 64 (6), e26347 [citations: 37]
 - K Stawiski, J Trelinska, D Baranska, I Dachowska, K Kotulska, S Jóźwiak, ... **What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods** *Magnetic Resonance Materials in Physics, Biology and Medicine* 2017: 30 (4), 397-405 [citations: 9]
 - A Puła, K Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak **A systematic review and meta-analysis of B-cell receptor signaling inhibitors in relapsed and refractory chronic lymphocytic leukemia** *LEUKEMIA & LYMPHOMA* 2017: 58, 152-153 [citations: 0]
 - A Puła, KG Stawiski, M Braun, E Iskierka-Jażdżewska, T Robak **Bezpieczeństwo i efektywność kliniczna nowych inhibitorów szlaku sygnałowego receptorów limfocytów B w leczeniu nawrotowej i opornej przewlekłej białaczki limfocytowej ...** *Acta Haematologica Polonica* 2017: 48 (Supl. 1) [citations: 0]
 - M Zakrzewska, W Fendler, K Stawiski, R Gruszka, K Zakrzewski, ... **Comparative Analysis of miRNA Expression in Pediatric Neuronal and Mixed Neuronal-Glia Tumors** *PEDIATRIC BLOOD & CANCER* 2017: 64, S318-S318 [citations: 0]
 - LJ Lee, BE Howitt, W Fendler, K Stawiski, P Bu, L Cho, D Chowdhury, ... **miRNA profiling in a case: Control study of African American women with uterine serous carcinoma (USC).** *Journal of Clinical Oncology* 2017: 35 (15_suppl), e17116-e17116 [citations: 0]
 - KM Elias, WF Fendler, K Stawiski, A Vitonis, RS Berkowitz, DW Cramer, ... **Serum MicroRNA Sequencing for Early Diagnosis of Invasive Ovarian Cancer.** *REPRODUCTIVE SCIENCES* 2017: 24, 87A-87A [citations: 0]
 - Ł Dzik, A Puła, K Stawiski, B Mudza, M Włodarczyk, A Dzik **Patients' awareness of the prevention and treatment of colorectal cancer** *Polish Journal of Surgery* 2015: 87, 459-463 [citations: 16]
 - K Stawiski, A Strzałka, A Puła, K Bijakowski **PancreApp: an innovative approach to computational individualization of nutritional therapy in chronic gastrointestinal disorders** *MEDINFO 2015: 2015: eHealth-enabled Health*, 325-328 [citations: 10]
 - A Strzałka, K Stawiski, A Kaczmarek, A Kuchareczko, M Polgaj, M Topol **Analiza zmienności morfologicznych i topograficznych w zakresie struktur nerwowych i mięśniowych jamy pachowej (axillary fossa) w kontekście ich ewentualnych implikacji klinicznych** *Wydawnictwo Uniwersytetu Medycznego w Gdańsku* 2013 [citations: 0]
 - Ł Kuncman, M Orzechowska, K Stawiski, M Masłowski **Ciażyńska, M Gottwald, L** [citations: 4]
 - K Elias, U Smyczyńska, K Stawiski, Z Nowicka, J Webber, J Kaplan, ... **Identification of BRCA1/2 mutation female carriers using circulating microRNA profiles screening: 10, 1** [citations: 0]
 - K Stawiski, Ł Kuncman, M Jobczyk, M Bilski, C Franzese, M Orzechowska, ... **Pre-Treatment Sacral Bone Geometry Predicts Radiation-Induced Lymphopenia in Prostate Cancer** *Available at SSRN: 650635* [citations: 0]

See the details on PubMed: <https://link.konsta.com.pl/pubmed>

Book chapters

- Konrad Stawiski, Łukasz Polak, Wojciech Fendler, Jarosław Drożdż. Evidence-based medicine w kardiologii. WIELKA INTERNA: Kardiologia część 1 - wydanie II. Medical Tribune Polska 2018.
- Konrad Stawiski, Jacek Fijuth. Sztuczna inteligencja w onkologii. Innowacyjna Onkologia: potrzeby, możliwości, system. PZW 2020. ISBN 978-83-200-6032-4

Teaching and invited lectures

- 2025: "Jak sztuczna inteligencja może wpłynąć na zwiększenie możliwości realizacji radioterapii - praktyka i perspektywa?", XI Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Łódź, Poland. [Program](#)
- 2025: "Radioterapia w miejscowo zaawansowanym raku odbytnicy - należy eskalować leczenie systemowe", Konferencja 4R "Dokąd zmierza nowoczesna radioterapia - Eskalacja czy Deeskalacja?", Poland. [Program](#)
- 2025: "Optymalizacja radio-chemioterapii po przezwłokowej resekcji (TMT) w raku pęcherza moczowego w świetle aktualnych badań", "MISSION POSSIBLE" - Precyzja i personalizacja w onkologii, CMEducation, Warsaw, Poland. [Program](#)
- 2025: "Leczenie trójmodalne vs cystektomia z leczeniem okołoperacyjnym - dla kogo co jest optymalnym wyborem?" - radiotherapist perspective, Uro-Onko Expert Meeting, CMEducation, Łódź, Poland. [Program](#)
- 2024: "Total Neoadjuvant Treatment w raku odbytnicy - czy jest już standardem? Kiedy eskalować, kiedy deeskalować intensywność leczenia?", VIII Konferencja 4R - Radioterapeuci Radioterapeutom, Warsaw, Poland. [Program](#)
- 2024: "Synergia leczenia celowanego i radioterapii w badaniach klinicznych", Precyzja i personalizacja - "MISSION POSSIBLE" w onkologii, CMEducation, Warsaw, Poland. [Program](#)
- 2024: "Pisanie prac naukowych w dobie AI", educational lecture/materials for Young PTRO. [Slides](#)
- 2023: "Odmienne twarze Greja - dawki biologicznie równoważne w zależności od sposobu frakcjonowania i lokalizacji anatomicznej", conference "Radioterapia stereotaktyczna w dobie leczenia celowanego", Warsaw, Poland. [Archived program](#)
- 2023: "Wyniki badania klinicznego - analiza oraz ocena wartości", postgraduate studies "Non-commercial Clinical Research - Design, Implementation and Management", Medical University in Wrocław, Poland.
- 2022: "Czy sztuczna inteligencja zastąpi człowieka w planowaniu leczenia promieniami?", X Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Łódź, Poland.
- 2022: "Deep artificial neural networks in the integration of the expression profile of circulating and intracellular miRNA molecules in pancreatic cancer patients", Łódź Oncology Days, Łódź, Poland.
- 2022: "Time series analysis", postgraduate studies "Elements of empirical research methodology in medicine and application of statistics in biomedical research", Medical University of Łódź, Poland.
- 2022: "Introduction to Data Mining methods and the STATISTICA Data Miner system", postgraduate studies "Elements of empirical research methodology in medicine and application of statistics in biomedical research", Medical University of Łódź, Poland.
- 2021-2022: "Data in clinical trials (CRF) and database management", postgraduate studies "Non-commercial Clinical Research - Design, Implementation and Management", Medical University in Wrocław, Poland.
- 2021-2022: "New Technologies in Clinical Trials. Big Data", postgraduate studies "Non-commercial Clinical Research - Design, Implementation and Management", Medical University in Wrocław, Poland.
- 2021: "Zastosowanie zaawansowanych narzędzi statystycznych i sztucznej inteligencji w prognozowaniu rokowania i odpowiedzi na leczenie w raku gruczołu krokowego", "Rak stercza - wielodyscyplinarne podejście do terapii po niepowodzeniu leczenia miejscowego i w chorobie z przerzutami", 90C webinar. [Program](#)
- 2021: "Testy diagnostyczne, modele predykcyjne (regresja logistyczna)", youngPTRO scientific-biostatistical workshops, Young Division of the Polish Society of Radiation Oncology. [Recording](#)
- 2019: "Kobiety w nauce", Pałacowy Salon Naukowy, Akademia Młodych Uczonych PAN, Jabłonna, Poland, with Beata Małachowska. [Event page](#)
- 2019: "Nauczanie głębokie jako technika zwiększania skuteczności biomarkerów molekularnych", IX Zjazd Polskiego Towarzystwa Radioterapii Onkologicznej, Łódź, Poland. [Archived program](#)
- 2018: "Data mining to discover ovarian cancer signature in the miRNA serum profile", Elias Lab Meeting, Brigham and Women's Hospital / Dana-Farber Cancer Institute, Boston, MA, USA.
- 2018: "From anatomy to artificial intelligence in oncology", local science-outreach conference, Poland.

Clinical trials - selected commercial studies

- **TALAPRO-2** (B9991040 / [NCT04052204](#)): Phase III randomized study of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer; role: subinvestigator / site clinical team, GU oncology and systemic-therapy interface.
- **NC-6004-009** ([NCT03771820](#)): Phase Ib/II study of NC-6004, a nanoparticulate cisplatin formulation, plus pembrolizumab in advanced solid tumors; role: subinvestigator.
- **KEYNOTE-867** (MK-3475-867 / [NCT03924869](#)): Phase III randomized study of pembrolizumab with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer; role: subinvestigator, chemoradiotherapy/immunotherapy setting.
- **KEYNOTE-689** (MK-3475-689 / [NCT03765918](#)): Phase III study of pembrolizumab as neoadjuvant and adjuvant treatment for resectable locally advanced head-and-neck squamous-cell carcinoma; role: subinvestigator.

- **CALLA** (D910SC00001 / [NCT04550260](#)): Phase III randomized study of durvalumab with chemoradiotherapy in locally advanced cervical cancer; role: subinvestigator, definitive chemoradiotherapy setting.

Research software, digital health projects and reproducible tools

- **rect-ril** ([Zenodo DOI: 10.5281/zenodo.19595346](#)) - R/Python analysis pipeline and interactive calculator for predicting severe radiation-induced lymphopenia in rectal cancer; role: creator/maintainer; output: calculator, reproducible analysis package, GitHub release, Zenodo DOI.
- **RTpipeline** - DICOM RT-to-analysis pipeline for dose-volume, radiomics, and machine-learning workflows; role: creator/maintainer; output: GitHub repository and [documentation](#).
- **Somatic Likelihood Tiering** - multi-evidence framework for tumor-only whole-exome sequencing variant triage; role: creator/maintainer; output: GitHub release and [Zenodo DOI: 10.5281/zenodo.19572621](#).
- **Prostate AS-counselling calculators** - open-access active-surveillance counselling calculators estimating biopsy-to-prostatectomy ISUP-upgrade risk (Jobczyk et al. 2026); role: creator/maintainer of the public calculators.
- **OmicSelector** - R/Docker framework for biomarker signature selection, feature selection, and deep-learning model development from high-throughput omics and multidimensional datasets; role: creator/maintainer; initially developed for miRNA-seq, RNA-seq, and qPCR.
- **Notatnik Medyczny** - selected digital-health project applying AI-assisted workflows to structured clinical documentation, including pre-visit intake, OCR, dictation, and quality-control components.
- **Notatnik Medyczny (ADK Prototype)** - public hackathon entry demonstrating selected AI-assisted medical-documentation functions.
- **Radioonkolog.pl** - clinical profile and patient information resource for radiotherapy consultations.
- **seq-pipeline** - workspace for data-science projects and NGS pipelines.
- **OmicApp** - Shiny application framework integrating OmicSelector and omics modeling workflows.
- **neurexam** - interactive neurological examination assistant and electronic health record.
- **PancrApp** - computational approach to individualizing nutritional therapy in chronic gastrointestinal disorders.

Certified courses

- 2025: **Clinical Scholars Research Training programme**, Harvard Medical School / Polish Medical Research Agency, advanced clinical research training.
- 2022: Single-cell RNA-seq data analysis workshop, Harvard Chan Bioinformatics Core (HBC), Boston, MA, USA
- 2022: Bulk RNA-seq data analysis workshop (part 1 and 2), Harvard Chan Bioinformatics Core (HBC), Boston, MA, USA
- 2016: "Computational Genomics" (Summer School), Max-Delbrück-Centre for Molecular Medicine, Berlin, Germany
- 2016: "Fundamentals of Digital Image and Video Processing" (Coursera ID: ULTLWMZSCYEZ), Northwestern University, Evanston, IL, USA

Skills

- Clinical radiation oncology: genitourinary and gastrointestinal cancers; bladder-preserving trimodality therapy, prostate and rectal radiotherapy, SBRT/SRS, brachytherapy, radiochemotherapy, radioimmunotherapy, clinical trials, ward/team leadership, and multidisciplinary oncology care.
- Translational oncology: radiomics, DICOM RT processing, dose-volume analytics, miRNA-seq, RNA-seq, single-cell RNA-seq, whole-exome sequencing, molecular biomarkers, radiation toxicity, and radiotherapy response modeling.
- AI and biostatistics: prediction modeling, survival analysis, machine learning, deep learning, data mining, model validation, clinical decision tools, and reproducible research workflows.
- Research software and digital-health projects: R, R Markdown, Shiny, Python, Docker, GitHub/Zenodo releases, web calculators, clinical documentation workflows, OCR, dictation, quality-control components, and secure web deployment.

Organizational activity

- 2024 - present: Editorial Board Member, **BMC Cancer** (Springer Nature).
- 2023 - 2026: Elected member, **ESTRO AI in RT Focus Group**, an international working group on artificial intelligence in radiation oncology.
- 2021 - present: Member of ESTRO (European Society for Radiotherapy and Oncology);
- 2019 - present: Member of the Polish Oncological Society;
- 2019 - present: Member of the Polish Society of Radiation Oncology;
- 2017 - 2018: Member of the program council, Kuźnia Młodych Talentów, Academy of Young Scholars of the Polish Academy of Sciences.
- 2014 - 2016: Individual Course of Studies at the Department of Biostatistics and Translational Medicine; tutor: Dr Wojciech Fendler;
- 2013 - 2015: **President of the Student Scientific Society of the Medical University of Lodz.**
- 2012 - 2013: Member of the Board of the Student Scientific Society of the Medical University of Lodz.
- 2012 - 2013: Individual Course of Studies at the Department of Neurosurgery and Oncology of the Nervous System; tutor: Dr Krzysztof Tybor;

- 2012 - 2015: Member of the Student Scientific Society at the Department of Neurosurgery;
- 2011 - 2015: Member of the Student Research Group at the Faculty of Normal and Clinical Anatomy;
- 2011 - 2015: International Association of Medical Students (IFMSA): (1) 2014: European Regional Meeting of Medicine Students, General Delegate of Poland, (2) 2013 - 2016: IFMSA New Technologies Support Division Director Assistant (international position), (3) 2013 - 2015: Member of the IFMSA-Poland marketing team (national position), (4) 2013 - 2015: IFMSA-Poland National New Technologies Director (national position), (5) 2012 - 2013: IFMSA-Poland National New Technologies Director Assistant (national position), (6) 2012 - 2013: Local coordinator of the project "Dying - a human thing" (local position), (7) 2011 - 2014: Local New Technologies Director (local position), (8) participation in 3 national IFMSA-Poland assemblies (Fall 2012, Spring 2012, Fall 2013).

This English CV was updated on 2026-07-13.